Literature DB >> 7534811

Antibodies to parvovirus B19 NS-1 protein in infected individuals.

A von Poblotzki1, A Gigler, B Lang, H Wolf, S Modrow.   

Abstract

Human parvovirus B19 is the aetiological agent of the common childhood disease erythema infectiosum (fifth disease). The infection is usually benign and self-limiting, but in adults cases of severe arthritis which may persist for years have been reported. Neutralizing antibodies directed against the structural proteins are usually produced shortly after the infection. The immune response against the third major protein, the non-structural protein NS-1, of parvovirus B19 has not been characterized so far. We cloned and expressed the full-length NS-1 protein and fragments thereof in Escherichia coli. The purified recombinant proteins were used to investigate the presence of antibodies to the NS-1 protein in sera from patients with parvovirus B19 infection. Specific antibodies could be detected in sera from patients suffering from severe parvovirus B19-associated arthritis using Western blot analysis and an ELISA. Sera from patients with acute or past infection without complications did not contain detectable levels of immunoglobulin to NS-1. The use of subfragments of the NS-1 protein allowed localization of the antigenic domains in the carboxy-terminal region of the protein.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534811     DOI: 10.1099/0022-1317-76-3-519

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  11 in total

Review 1.  Pathogenesis of human parvovirus B19 in rheumatic disease.

Authors:  J R Kerr
Journal:  Ann Rheum Dis       Date:  2000-09       Impact factor: 19.103

2.  Sequence analysis of a parvovirus B19 isolate and baculovirus expression of the non-structural protein.

Authors:  K E Hicks; R C Cubel; B J Cohen; J P Clewley
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Regulation of tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2.

Authors:  Yi Fu; Keiko Kumura Ishii; Yasuhiko Munakata; Takako Saitoh; Mitsuo Kaku; Takeshi Sasaki
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

Review 4.  Human Parvoviruses.

Authors:  Jianming Qiu; Maria Söderlund-Venermo; Neal S Young
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

5.  Characterization of cis-acting and NS1 protein-responsive elements in the p6 promoter of parvovirus B19.

Authors:  R Gareus; A Gigler; A Hemauer; M Leruez-Ville; F Morinet; H Wolf; S Modrow
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

6.  Generation of neutralizing human monoclonal antibodies against parvovirus B19 proteins.

Authors:  A Gigler; S Dorsch; A Hemauer; C Williams; S Kim; N S Young; S Zolla-Pazner; H Wolf; M K Gorny; S Modrow
Journal:  J Virol       Date:  1999-03       Impact factor: 5.103

Review 7.  Human parvovirus B19.

Authors:  Erik D Heegaard; Kevin E Brown
Journal:  Clin Microbiol Rev       Date:  2002-07       Impact factor: 26.132

8.  Lymphoproliferative responses after infection with human parvovirus B19.

Authors:  A von Poblotzki; C Gerdes; U Reischl; H Wolf; S Modrow
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Global co-existence of two evolutionary lineages of parvovirus B19 1a, different in genome-wide synonymous positions.

Authors:  Marijke W A Molenaar-de Backer; Vladimir V Lukashov; Rob S van Binnendijk; Hein J Boot; Hans L Zaaijer
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240

10.  Gene expression analysis of potential genes and pathways involved in the pathogenic mechanisms of parvovirus B19 in human colorectal cancer.

Authors:  Wei-Ping Zhang; Hua Yang; Hong Chen; Hai-Rong Zhu; Quan Lei; Yun-Hong Song; Zhong-Ming Dai; Jing-Shan Sun; Li-Li Jiang; Zhan-Guo Nie
Journal:  Oncol Lett       Date:  2014-05-16       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.